Literature DB >> 20644160

Delaying bacillus Calmette-Guérin vaccination from birth to 4 1/2 months of age reduces postvaccination Th1 and IL-17 responses but leads to comparable mycobacterial responses at 9 months of age.

Sarah Burl1, Uche J Adetifa, Momodou Cox, Ebrima Touray, Martin O Ota, Arnaud Marchant, Hilton Whittle, Helen McShane, Sarah L Rowland-Jones, Katie L Flanagan.   

Abstract

Bacillus Camette-Guérin (BCG) vaccine is the only licensed vaccine against tuberculosis, yet its protective efficacy is highly variable between different geographical regions. We hypothesized that exposure to nontuberculous mycobacteria attenuates BCG immunogenicity by inducing mycobacterial-specific regulatory T cells (Tregs). Gambian neonates were recruited at birth and randomized to receive BCG vaccination either at birth or at 4 1/2 mo. Mycobacterial immune responses were assessed at birth, 4 1/2, and 9 mo of age. At 4 1/2 mo of age the BCG naive individuals had detectable mycobacterial responses, including increased IL-10 production suggesting environmental priming. Vaccination at birth significantly enhanced Th1, Th2, IL-6, IL-17, and Treg responses in mycobacterial cultures at 4 1/2 mo compared with the BCG naive group. Analyzing results at 4 1/2 mo postvaccination revealed lower IFN-gamma, IL-6, and IL-17 responses in the delayed BCG vaccine group compared with those vaccinated at birth, but this did not relate to Treg levels prevaccination. When comparing responses pre- and post-BCG vaccination in the delayed vaccine group, there was no priming of mycobacterial IL-17. Mycobacterial responses waned over 9 mo in those vaccinated at birth, leading to comparable mycobacterial immunity in both groups at 9 mo of age. Overall, these data suggest that vaccination at birth induces a broad Th1/Th2/IL-17/Treg mycobacterial response but the Th1/Th-17 response was reduced when delaying the vaccine. The evidence did not suggest that mycobacterial specific naturally occurring Tregs accounted for this attenuated immunogenicity.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20644160     DOI: 10.4049/jimmunol.1000552

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  46 in total

Review 1.  Tuberculosis vaccines in clinical trials.

Authors:  Rosalind Rowland; Helen McShane
Journal:  Expert Rev Vaccines       Date:  2011-05       Impact factor: 5.217

Review 2.  Factors That Influence the Immune Response to Vaccination.

Authors:  Petra Zimmermann; Nigel Curtis
Journal:  Clin Microbiol Rev       Date:  2019-03-13       Impact factor: 26.132

Review 3.  Protection versus pathology in tuberculosis: recent insights.

Authors:  Andrea M Cooper; Egidio Torrado
Journal:  Curr Opin Immunol       Date:  2012-05-19       Impact factor: 7.486

4.  Neonatal vaccination with bacille Calmette-Guérin promotes the dendritic development of hippocampal neurons.

Authors:  Qingqing Li; Yuwei Zhang; Juntao Zou; Fangfang Qi; Junhua Yang; Qunfang Yuan; Zhibin Yao
Journal:  Hum Vaccin Immunother       Date:  2015-09-16       Impact factor: 3.452

5.  Immunogenicity of BCG in HIV-exposed and non-exposed infants following routine birth or delayed vaccination.

Authors:  A C Hesseling; H B Jaspan; G F Black; N Nene; G Walzl
Journal:  Int J Tuberc Lung Dis       Date:  2015-04       Impact factor: 2.373

6.  The tuberculin skin test (TST) is affected by recent BCG vaccination but not by exposure to non-tuberculosis mycobacteria (NTM) during early life.

Authors:  Sarah Burl; Uche J Adetifa; Momodou Cox; Ebrima Touray; Hilton Whittle; Helen McShane; Sarah L Rowland-Jones; Katie L Flanagan
Journal:  PLoS One       Date:  2010-08-19       Impact factor: 3.240

Review 7.  Innate immune function by Toll-like receptors: distinct responses in newborns and the elderly.

Authors:  Tobias R Kollmann; Ofer Levy; Ruth R Montgomery; Stanislas Goriely
Journal:  Immunity       Date:  2012-11-16       Impact factor: 31.745

8.  Delaying BCG vaccination until 8 weeks of age results in robust BCG-specific T-cell responses in HIV-exposed infants.

Authors:  Christophe Toukam Tchakoute; Anneke C Hesseling; Elvis B Kidzeru; Hoyam Gamieldien; Jo-Ann S Passmore; Christine E Jones; Clive M Gray; Donald L Sodora; Heather B Jaspan
Journal:  J Infect Dis       Date:  2014-08-08       Impact factor: 5.226

9.  Bacillus Calmette-Guérin vaccination at birth and in vitro cytokine responses to non-specific stimulation. A randomized clinical trial.

Authors:  T N Nissen; N M Birk; B A Blok; R J W Arts; A Andersen; J Kjærgaard; L M Thøstesen; T Hoffmann; D L Jeppesen; S D Nielsen; P-E Kofoed; L G Stensballe; P Aaby; M Ruhwald; M G Netea; C S Benn; O Pryds
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2017-09-10       Impact factor: 3.267

Review 10.  Current status of new tuberculosis vaccine in children.

Authors:  Yu Pang; Aihua Zhao; Chad Cohen; Wanli Kang; Jie Lu; Guozhi Wang; Yanlin Zhao; Suhua Zheng
Journal:  Hum Vaccin Immunother       Date:  2016-03-22       Impact factor: 3.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.